Brought to you by 
Pfizer licenses proteomics technology ProteoGraph from OGS
13 Jan 2003
Executive Summary
Oxford GlycoSciences will use its ProteoGraph proteomics technology on Pfizer's tissue samples to build Pfizer a database of proteins that are overexpressed in Alzheimer's patients. The companies will jointly own the resulting intellectual property.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer licenses proteomics technology ProteoGraph from OGS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice